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Introduction
The scientific rationale for systematic
reviews of animal studies was first outlined
in an influential commentary published in
2002 [1]. The authors drew attention to
the need for more rigorous assessment of
animal studies before beginning studies in
patients. They suggested that systematic
reviews of all relevant animal experiments
should be a prerequisite for the design of
new clinical trials. Their concerns were
prompted by a systematic review of animal
studies of Nimodipine in focal cerebral
ischemia, which showed insufficient evi-
dence to justify involvement of over 7,000
patients in drug trials [2].
We summarize developments since
2002, focusing on the scientific rationale
for systematic reviews of animal studies
and the limitations and pitfalls. Moreover,
we suggest further improvements in ani-
mal research to maximise its contribution
to evidence-based translational research.
Translational Challenges
Although it may be preferable to study
humans when seeking knowledge about
human biology or the human response to
interventions, it may be unethical or
unfeasible. In these circumstances animal
models are regularly used. One of the
advantages of animal studies is the ability
to study a relatively homogeneous group
of animals instead of a heterogeneous
group of patients. In addition, animal
studies offer a wider range of possibilities
to examine toxicity of interventions or
study pathology and mechanisms of dis-
ease; most clinical trials only focus on
clinical efficacy. Nevertheless, new thera-
pies or interventions shown to be effective
in animal studies are often less effective or
ineffective in clinical trials [3]. Sometimes,
interventions are even harmful to humans
[2,4,5].
Several challenges exist to successfully
translating the outcomes from animal
research to humans in a clinical setting:
(1) Biological differences between spe-
cies and strains
Genetic and species differences between
animals and humans, but also within
animal species, strains, and cell lines are
often disregarded in the design of animal
studies [6–8]. Ignoring biological differ-
ences between species and strains results in
flawed design and unreliable outcomes,
incurs unnecessary costs, and uses more
experimental animals than necessary.
(2) Poor methodological quality of
animal experiments
In many animal experiments, important
methodological issues, such as randomiza-
tion and blinding, are neglected [9–12]. In
addition, the statistical methods used to
analyze results are often flawed [11].
These failures mean that basic research
cannot be replicated and may cause an
overestimation of the efficacy of interven-
tions [13]. Although clinical trials in
humans also suffer from biases, preclinical
animal studies appear to be associated
with even greater risks [14].
(3) Differences in the design of experi-
mental animal studies and clinical trials
Animal studies designed to decide
whether or not to take an intervention
forward to clinical trials, use study proto-
cols that differ from clinical studies. For
example, many of the animal studies
investigating the effect of probiotics on
pancreatitis administered probiotics before
inducing pancreatitis, whereas in the
clinical trial probiotics were given to
patients already presenting with signs of
pancreatitis [5].
(4) Insufficient reporting of details of
animals, methods, and materials
Characteristics of the design of animal
studies, such as the strain, gender, age and
weight, and housing conditions of the
animals used, are known to influence
results. Failures in reporting these details
skew the interpretation of study results and
subsequent translation into clinical bene-
fits.
(5) Publication bias
Not reporting experiments with nega-
tive or neutral results leads to an overes-
timation of the effect of an intervention
[15]. Publication bias plays a role in both
clinical trials and animal studies, but is
believed to be more problematic in animal
studies (14). In experimental stroke studies,
for example, an estimated 14% of animal
studies are unreported [16].
Scientific Rationale for
Systematic Reviews of Animal
Studies
In light of these translational challenges,
it is no surprise that results in clinical trials
often deviate from results of animal studies
[17]. Systematic reviews are an important
part of the solution because of the need to
better understand how animal research
informs clinical research [18–22].
By systematically reviewing the litera-
ture and ensuring that all animal studies
are published regardless of outcome,
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unnecessary duplication of often expensive
animal experiments can be reduced [23].
Moreover, systematic reviews can contrib-
ute to improving translation of animal
research to humans in several ways:
information about safety and efficacy of
treatments that is hard to obtain from
individual studies; misinterpretation of
evidence is diminished because systematic
reviews expose biases and inadequacies in
the methodology of individual studies [24];
and differences in design between animal
studies, and between animal and human
studies, become transparent, and the most
optimal animal models for evaluating a
treatment before testing in humans can be
selected [25,26].
Systematic reviews of animal studies
also have limitations. First, reviews are
time consuming. Second, because of poor
reporting and methodological inadequa-
cies in animal studies, reviews may be
unable to produce precise and reliable
overall effect estimates. For now, system-
atic reviews should be primarily used to
determine the direction of the effect, and
the factors affecting the size and direction
of the effect. Third, systematic reviews will
be unable to address the issue of the low
external validity of (certain) animal models
to the extent that this is due to biological
differences between humans and other
animal species. [27]. Nevertheless, overall,
the advantages of systematic reviews
outweigh the limitations.
Improving the Translational
Value of Animal Studies
Since 2002, when the scientific rationale
for systematic reviews of animal studies
was published [1], important develop-
ments and initiatives have aimed to
improve the quality and translational
value of animal research:
(i) Quality of study conduct, reporting,
and replication
In 2009, the NC3Rs surveyed the
quality of reporting, experimental design,
and statistical analysis in 271 published
animal studies [11]. The survey revealed a
number of weaknesses in experimental
design, statistical analysis, and reporting,
and prompted publication of two sets of
guidelines. The Animal Research: Report-
ing In Vivo Experiments (ARRIVE)
guidelines [28] and the Gold Standard
Publication Checklist (GSPC) [29] are
based on the CONSORT guidelines for
reporting clinical trials, and offer checklists
for improving reporting of animal re-
search. These initiatives may help to
reduce bias in the conduct and reporting
of animal studies, and thereby improve
their predictive value [12]. Major scientific
and medical journals have included the
ARRIVE guidelines in their guidance to
authors, and The Netherlands Organisa-
tion for Health Research and Develop-
ment (ZonMW) urges researchers who
receive funding from this organisation to
use the GSPC. Moreover, in the UK, the
Wellcome Trust, the Biotechnology and
Biological Sciences Research Council, and
the Medical Research Council have signed
up to the ARRIVE guidelines. ZonMW
has also issued a special funding pro-
gramme for further development of edu-
cation and supervision in this field.
Furthermore, an online interactive educa-
tional programme, known as 3Rs-REDUC-
TION (http://www.3rs-reduction.co.uk/)
has been developed for researchers to
improve the design of animal experiments
and to better consider genetic variation in
animal (toxicology) testing. Workshops ar-
ranged by the Fund for the Replacement of
Animals in Medical Experiments (FRAME)
complement this programme, and aim to
educate animal researchers in methods and
practices to use the minimum number of
animals necessary for achieving the objectives
of a study.
A key feature of good experimental
practice is reproducibility. Reproducibili-
ty, or the lack of it, is a familiar issue for
the scientific community, and the Science
Exchange, PLOS ONE, Figshare, and
Mendeley have recently launched the
Reproducibility Initiative (https://www.
scienceexchange.com/reproducibility).
This initiative aims to identify and
reward high quality, reproducible re-
search. Results can be submitted for
independent and ‘‘blinded’’ validation.
Validated studies receive a ‘‘Certificate of
Reproducibility,’’ acknowledging that
their results have been independently
reproduced as part of the Reproducibility
Initiative. Scientists are able to publish the
replicated results as an independent pub-
lication in the PLOS ONE Reproducibility
Collection, and can share their data using
the Figshare Reproducibility Collection
repository. The director of the US Na-
tional Office of Public Health Genomics
says that the initiative ‘‘will begin to
address huge gaps in the first of many
translational steps from scientific discover-
ies to improving health.’’
(ii) Systematic reviews and meta-analy-
ses
Other initiatives are directly focused on
the conduct of systematic reviews and
meta-analysis of animal studies. In 2004,
Pound and colleagues [30] called for a
large-scale programme of systematic re-
views of animal studies to help improve
the quality of evidence derived from
animal data. That same year, the chair
of the National Institute for Clinical
Excellence called for ‘‘detailed scrutiny of
the totality of all the available evidence’’ to
assess the ‘‘real predictive power’’ of the
preclinical biological studies used in the
research and development process [31].
In response to these appeals, an inter-
national group of animal researchers
established the Collaborative Approach
to Meta Analysis and Review of Animal
Data from Experimental Studies (CA-
MARADES). This group focused particu-
larly on systematic reviews of animal
studies evaluating interventions for stroke
and other neurological conditions.
In 2005, the Nuffield Council on
Bioethics published a report stressing that
more systematic reviews of animal studies
are needed to understand the ethical and
scientific issues in animal research [32],
and urged funders of animal research to
Summary Points
N During the last decade, new developments and initiatives have been
introduced to improve the quality and translational value of animal research.
We summarize these here, focusing on quality of study conduct, reporting, and
replication; systematic reviews and meta-analyses; and study registration,
publication bias, and data sharing.
N Systematic reviews of animal studies should be conducted routinely. Funding
agencies should subsidize systematic reviews, not simply for transparency, but
also to avoid waste of financial resources and unnecessary duplication of animal
studies.
N An international register for animal studies should be established and funded.
Journals should publish ‘‘negative and neutral’’ results, and promote data
sharing.
N Improving the quality and translation of animal research requires co-operation
from the wider scientific community, journals, researchers, regulators, funding
bodies, peer reviewers, and patients. Systematic reviews of preclinical studies
should be included in the Cochrane Library.
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support systematic reviews. Simultaneous-
ly, the American Council on Science and
Health called on US government agencies
to adopt new guidelines for toxicology
studies to identify cancer-inducing sub-
stances. The council insisted that modern
methods be used to review systematically
‘‘the totality of evidence from animal
studies, just as is done for studies on
humans, rather than giving excessive
weight to any one or two animal test
results in one species’’ [33]. At the same
time, a British charity, SABRE Research
UK, was established by patients and
researchers to promote systematic reviews
of animal studies for better health care,
and to protect patients and research
volunteers from unsound research.
In 2008, the SYstematic Review Centre
for Laboratory animal Experimentation
(SYRCLE, previously named 3R Re-
search Centre) was established in Nijme-
gen (The Netherlands) to improve the
scientific quality and transparency of
animal research, and to develop educa-
tional material and guidelines for system-
atic reviews of animal studies. In 2012, the
Dutch Parliament adopted a motion in
which the government was requested to
ensure that systematic reviews also become
the norm for animal experiments, just as is
the case for clinical studies.
Although it is too early to provide
evidence that systematic reviews lead to
improved translational value of animal
research, there are some examples
[3,34,35]. The systematic review of Hirst
et al., which was conducted after estab-
lishment of temozolomide as first line
chemotherapy for malignant glioma,
showed that temozolomide, also improved
survival and reduced tumour volume in
experimental glioma, just like in humans,
even after accounting for publication bias
[34]. In addition, the design of an ongoing
trial on hypothermia in acute ischemic
stroke (EuroHYP-1) was explicitly based
on a systematic review of animal data [35].
Evidence-based selection of animal models
will also improve translation, as the use of
less suitable animal models is decreased
[8,25].
Scientists are increasingly convinced of
the need of systematic reviews of animal
studies. The number of systematic reviews
of animal studies increased from 86 to 244
between 2005 and 2010. However, sys-
tematic reviews of animal studies are still
relatively rare [15].
(iii) Study registration, publication bias,
and data sharing
Obtaining data originating from pre-
clinical animal studies is a priority, and
calls have been made for prospective
registration of all animal experiments
[3,24]. Although a registration system
does not currently exist, initiatives have
begun. The Dutch parliament adopted a
second motion in February 2012 that
defined a general database/registry of
animal studies with the aim of preventing
unnecessary duplication and reducing
publication bias. The Netherlands Knowl-
edge Centre on Alternatives to animal use
(NKCA) is tasked with outlining the steps
needed to implement this motion. A
register of animal studies has different
pitfalls and challenges compared to a
registry of clinical studies.
Another strategy for obtaining data
originating from preclinical animal studies,
is publishing negative and neutral results,
and promoting data sharing. In 2012,
Begley and Ellis called for opportunities to
present negative data, and suggested that
journal editors should initiate this cultural
change [36]. In addition, funding agencies
and reviewers must acknowledge that
negative data are just as useful as positive
data. The Dutch ZonMw recently devel-
oped a special funding programme for
animal research entitled, ‘‘More knowl-
edge with fewer animals,’’ including a
module providing funding to scientists for
publishing negative or neutral results.
Several initiatives aimed at data sharing
are being developed. First, REACH, the
European Community Regulation on
chemicals and their safe use (EC 1907/
2006) (http://echa.europa.eu/chemicals-
in-our-life/animal-testing-under-reach) en-
courages information from tests to establish
that the hazardous properties of chemicals
are shared between registrants. Sharing of
results of tests in vertebrate animals is
already mandatory. The European Chem-
icals Agency, ECHA, facilitates sharing of
data and information by companies, scien-
tists, and citizens.
Second, Figshare was launched in 2011.
Figshare allows researchers to publish
research findings in an easily citable,
sharable, and discoverable manner. By
opening up the peer review process,
researchers can publish neutral results,
avoid the file drawer effect, and help make
scientific research more efficient. Figshare
uses creative commons licensing to share
research data and allow users to retain
ownership.
Third, F1000Research, the first open
science journal, was launched in 2012.
It is an open access journal for life
scientists, offering immediate publica-
tion, transparent post-publication peer
review, and full data deposition and
sharing. All scientifically sound articles
are accepted. This revolutionary devel-
opment ensures and stimulates full
openness and transparency.
Future Horizons
Although these initiatives are promising,
there is no room for complacency. We
must start by converting ideas into daily
scientific practice.
More systematic reviews of animal
studies are needed. Making systematic
reviews of animal studies a routine is our
scientific and societal responsibility, just as
with clinical studies in humans. As a
minimum, we urge researchers to conduct
a systematic search for all relevant exper-
imental animal studies before designing or
starting a new animal experiment or
clinical trial.
An international initiative to register
animal studies must be started. In addi-
tion, journal editors must accept publica-
tions with so-called negative and neutral
results, and promote data sharing.
Funding agencies should stimulate and
fund systematic reviews. A recent article
on forbes.com estimates that some major
drug companies spend between US$4–
$US11 billion per drug, once failure rates
are factored in. Systematic reviews disclose
inadequacies in methodology of individual
studies. This helps improve future study
design, and reduce failure rate of animal
studies of new drugs [23].
Specifically, funding agencies can man-
date systematic reviews of animal experi-
ments as part of a funding. This will make
the choice of animal models more evi-
dence-based and provide better protection
for human patients.
From a societal, ethical, and scientific
perspective, laboratory animals must be
used more efficiently. Better training of
scientists who intend to work with animals,
and improved research methods will assist
the translational process, help the eco-
nomic and ethical aspects of animal
studies, and promote better health care
and improved safety for patients and
research participants.
Achieving success will depend upon co-
operation between scientific journals, authors,
animal research regulators, funding bodies,
and peer reviewers. Progress also depends on
the clinical research community demanding
better quality pre-clinical research, and
finding ways to improve communication with
animal researchers whose pre-clinical work
they may rely on [3].
Finally, a big step forward would be for
organizations focused on systematic re-
views of animal data, such as SYRCLE
and CAMARADES, to join the worldwide
network of the Cochrane Collaboration to
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improve links and cross-fertilisation be-
tween preclinical and clinical research,
and facilitate translation from ‘‘bench to
bedside.’’
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